About half of people with heart disease have a specific pattern of fatty particles in their blood that includes too many harmful fats and not enough protective ones.
Scientific Claim
Atherogenic lipoprotein profile — characterized by elevated IDL, triglycerides, dense LDL, dense VLDL, and low HDL-2 — is present in 40% to 50% of patients with coronary artery disease.
Original Statement
“A form of dyslipidemia, the atherogenic lipoprotein profile, that consists of elevated intermediate-density lipoprotein (IDL), triglycerides (TGs), dense LDL and dense very low density lipoprotein (VLDL), and low high density lipoprotein-2, occurs in 40% to 50% of patients with coronary artery disease (CAD).”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design cannot support claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The claim reports a prevalence rate from summarized studies, using neutral descriptive language. No causal verbs are used, and the percentage is directly quoted. The review does not overstate — it accurately reports a summary finding.
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Systematic Review & Meta-AnalysisLevel 1aThe pooled prevalence of the atherogenic lipoprotein profile among patients with confirmed CAD across diverse populations and measurement methods.
The pooled prevalence of the atherogenic lipoprotein profile among patients with confirmed CAD across diverse populations and measurement methods.
What This Would Prove
The pooled prevalence of the atherogenic lipoprotein profile among patients with confirmed CAD across diverse populations and measurement methods.
Ideal Study Design
A meta-analysis of 15+ studies using standardized criteria (e.g., NMR or ultracentrifugation) to define the atherogenic profile in 10,000+ patients with angiographically confirmed CAD, stratified by ethnicity, diabetes status, and lipid measurement technique.
Limitation: Cannot determine if the profile causes CAD or is a consequence of it.
Prospective Cohort StudyLevel 2bWhether the atherogenic lipoprotein profile is consistently present in CAD patients across different healthcare settings and measurement protocols.
Whether the atherogenic lipoprotein profile is consistently present in CAD patients across different healthcare settings and measurement protocols.
What This Would Prove
Whether the atherogenic lipoprotein profile is consistently present in CAD patients across different healthcare settings and measurement protocols.
Ideal Study Design
A multicenter prospective cohort of 5,000 patients with newly diagnosed CAD, with standardized lipid profiling using NMR within 72 hours of diagnosis, to determine the proportion meeting predefined atherogenic profile criteria.
Limitation: May be biased by selection of patients referred for angiography.
Evidence from Studies
Supporting (1)
The role of non-LDL:non-HDL particles in atherosclerosis
The study says that about half of people with heart disease have a specific unhealthy fat pattern in their blood — exactly what the claim says. So the study supports the claim.